Pazopanib

Pazopanib

Another Name
Votrient,Pazopanib, 帕唑帕尼
Indications
Renal Cell Carcinoma (RCC), Soft Tissue Sarcoma (STS)
Reg No
03L1321/25
Inspection No
550-25
dosage form:Tablets
Specs:200mg * 200Tablets
Indate:2 Years
Date：2025-4-6 Views：875
Drug Info

Composition:

Each film-coated tablet contains Pazopanib hydrochloride 216.7 mg equivalent to Pazopanib……………………200 mg

Indication:

LuciPazo is a kinase inhibitor indicated for the treatment of adults with:

  • Advanced renal cell carcinoma (RCC).
  • Advanced soft tissue sarcoma (STS) who have received prior chemotherapy.

Dosage and Use:

  • Recommended Dosage: 800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal).
  • Moderate Hepatic Impairment: 200 mg orally once daily.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/pazopanib/

Related News